McDermott + Bull has successfully placed Frances Tan as the Assistant Controller for Geron Corporation. Reporting to the Controller, Frances and her team will be responsible for supporting the accounting function, with specific responsibility for accounts payable, payroll, general ledger, and cash management. She will also ensure compliance with internal controls, drive continuous improvement and efficient workflow in accounting, and ensure timely and accurate issuance of the monthly financial statements.
Prior to joining Geron, Frances was the Assistant Controller at Tricida and the Senior Accounting Manager at Pacific Biosciences. She has a strong background in public accounting for mid-market to larger public companies and possesses strategic, technical, and financial leadership capabilities. Her strong work ethic and commitment will play an integral role in the financial management of Geron.
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies.
This executive search was completed by McDermott + Bull Partner Garrett Lipus, Managing Director Linda Sierra, Director Tim Dotson, and Executive Recruiter Quyen Doan.